Drug Profile


Alternative Names: PLX-3397

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Plexxikon
  • Developer Array BioPharma; AstraZeneca; Barbara Ann Karmanos Cancer Institute; Centre Leon Berard; Columbia University; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Plexxikon; University of California at San Francisco
  • Class 2 ring heterocyclic compounds; Antineoplastics; Fluorine compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Immunomodulators; Macrophage colony stimulating factor inhibitors; Protein kinase inhibitors; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pigmented villonodular synovitis
  • Phase II Alzheimer's disease; Glioblastoma; Malignant melanoma; Prostate cancer
  • Phase I/II Breast cancer; Leukaemia; Peripheral nervous system diseases; Sarcoma; Solid tumours
  • Phase I Colorectal cancer; Gastrointestinal stromal tumours; Pancreatic cancer
  • No development reported Neurological disorders; Rheumatoid arthritis
  • Discontinued Acute myeloid leukaemia; Hodgkin's disease

Most Recent Events

  • 03 Oct 2017 Daiichi plans a phase I pharmacokinetics trial in USA, South Korea, Netherlands, New Zealand and Taiwan (NCT03291288)
  • 08 Aug 2017 Plexxikon temporarily terminates phase II trial in Alzheimer’s disease in Denmark before August 2017 (EudraCT2016-000429-38)
  • 02 Jun 2017 Adverse events and pharmacokinetics data from a phase I/II trial in Solid tumours and Leukaemia presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top